Last reviewed · How we verify
A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose
The purpose of this study is to compare the relative bioavailability of JNJ-64565111 between subcutaneous (SC) administrations in the upper arm versus the abdomen, and between SC administrations in the thigh versus the abdomen in otherwise healthy overweight/obese participants (Part A) and to assess the gastrointestinal tolerability of JNJ-64565111 following a dose titration in otherwise healthy obese participants at 6 weeks (Part B).
Details
| Lead sponsor | Janssen Research & Development, LLC |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 52 |
| Start date | Fri Jun 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Mar 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Obesity
Interventions
- JNJ-64565111
Countries
United States